ŠPINAROVÁ, Monika, Jindřich ŠPINAR, Lenka ŠPINAROVÁ, Jan KREJČÍ, Monika PÁVKOVÁ GOLDBERGOVÁ, Jiří PAŘENICA, Ondřej LUDKA, Filip MALEK, Petr OSTADAL, Klára BENEŠOVÁ, Jiří JARKOVSKÝ a Karel LÁBR. Relation between Mid-Regional Pro-Adrenomedullin in Patients with Chronic Heart Failure and the Dose of Diuretics in 2-Year Follow-Up-Data from FAR NHL Registry. Medicina-Lithuania. Basel: MDPI, 2022, roč. 58, č. 10, s. 1-10. ISSN 1010-660X. Dostupné z: https://dx.doi.org/10.3390/medicina58101477.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Relation between Mid-Regional Pro-Adrenomedullin in Patients with Chronic Heart Failure and the Dose of Diuretics in 2-Year Follow-Up-Data from FAR NHL Registry
Autoři ŠPINAROVÁ, Monika (203 Česká republika, domácí), Jindřich ŠPINAR (203 Česká republika, domácí), Lenka ŠPINAROVÁ (203 Česká republika, domácí), Jan KREJČÍ (203 Česká republika, domácí), Monika PÁVKOVÁ GOLDBERGOVÁ (203 Česká republika, domácí), Jiří PAŘENICA (203 Česká republika, domácí), Ondřej LUDKA (203 Česká republika, domácí), Filip MALEK (203 Česká republika), Petr OSTADAL (203 Česká republika), Klára BENEŠOVÁ (203 Česká republika, domácí), Jiří JARKOVSKÝ (203 Česká republika, domácí) a Karel LÁBR (203 Česká republika, garant, domácí).
Vydání Medicina-Lithuania, Basel, MDPI, 2022, 1010-660X.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30201 Cardiac and Cardiovascular systems
Stát vydavatele Švýcarsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 2.600
Kód RIV RIV/00216224:14110/22:00128072
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.3390/medicina58101477
UT WoS 000873135400001
Klíčová slova anglicky chronic heart failure; mid-regional pro-adrenomedullin; diuretics; furosemide; prognosis
Štítky 14110115, 14110211, 14110228, 14110518, 14119612, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 18. 1. 2023 09:47.
Anotace
Background and Objectives: The aim of this paper is to evaluate the impact of humoral substance mid-regional pro-adrenomedullin (MR-proADM) on the two-year survival of patients with chronic heart failure and relate it to the dosage of furosemide. Materials and Methods: The data is taken from the stable systolic heart failure (EF < 50%) FAR NHL registry (FARmacology and NeuroHumoraL activation). The primary endpoint at two-year follow-up was death, heart transplantation, or LVAD implantation. Results: A total of 1088 patients were enrolled in the FAR NHL registry; MR-proADM levels were available for 569 of them. The mean age was 65 years, and 81% were male. The aetiology of HF was ischemic heart disease in 53% and dilated cardiomyopathy in 41% of patients. The mean EF was 31 ± 9%. Statistically significant differences (p < 0.001) were obtained in several parameters: patients with higher MR-proADM levels were older, rated higher in NYHA class, suffered more often from lower limb oedema, and had more comorbidities such as hypertension, atrial fibrillation, diabetes, and renal impairment. MR-proADM level was related to furosemide dose. Patients taking higher doses of diuretics had higher MR-proADM levels. The mean MR-proADM level without furosemide (n = 122) was 0.62 (±0.55) nmol/L, with low dose (n = 113) 1–39 mg/day was 0.67 (±0.30) nmol/L, with mid dose (n = 202) 40–79 mg/day was 0.72 (±0.34) nmol/L, with high dose (n = 58) 80–119 mg/day was 0.85 (±0.40) nmol/L, and with maximum dose (n = 74) ≥120 mg/day was 1.07 (±0.76) nmol/L, p < 0.001. Patients with higher MR-proADM levels were more likely to achieve the primary endpoint at a two-year follow-up (p < 0.001) according to multivariant analysis. Conclusions: Elevated plasma MR-proADM levels in patients with chronic heart failure are associated with an increased risk of death and hospitalization. Higher MR-proADM levels in combination with increased use of loop diuretics reflect residual congestion and are associated with a higher risk of severe disease progression.
VytisknoutZobrazeno: 13. 7. 2024 19:59